“Durability of Efficacy and Safety of Roflumilast Cream 0.3% in Adults With Chronic Plaque Psoriasis From a 52-Week, Phase 2 Open-Label Safety Trial”, J of Skin, vol. 7, no. 4, p. s218, Jul. 2023, doi: 10.25251/skin.7.supp.218.